NRXS
$7.21
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
Recent News
Top Stock Reports for Meta, Bank of America & Procter & Gamble
Meta Platforms leads today's Zacks Research Daily as analysts highlight strong user growth, heavier AI investment and lingering concerns around monetization.
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth
NeurAxis posts its fifth straight quarter of double-digit expansion, but rising costs and margin pressure weigh on third-quarter 2025 results.
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis
Zacks highlights Alphabet, IBM, Merck, SandRidge Energy, and NeurAxis, providing research insights on their growth prospects, market performance, and key risks for investors.
Top Research Reports for Alphabet, IBM & Merck
Alphabet, IBM, and Merck headline Zacks' latest research reports, with insights spanning AI, cloud growth, and pipeline challenges.
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth
NRXS reports strong second-quarter 2025 revenue growth and lower losses, but gross margin compression remains a key concern.